Drugs / Oxybutynin XL
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02327936 Comparator | Dec 2014 → Mar 2018 | overactive bladder | Stéphane Bolduc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxybutynin XL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02327936 ↗ |
| Action | Inhibit | “Oxybutynin is the most widely antimuscarinic agent used in the pediatric population” NCT02327936 ↗ |
| Route | Oral | “Eligible subjects will be randomized to 8 weeks of single-blind treatment with Fesoterodine 4 mg Po Die or Oxybutynin XL 10 mg Po Die.” NCT02327936 ↗ |